
Published
22 September 2011 | By Kinapse
The pharmaceutical industry is experiencing an extended phase of consolidation in an attempt to realise economies of scale and mitigate risks. Kinapse analysis suggests that Big Pharma might now be too big and shows how to break it into smaller operating entities to help increase R&D productivity.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory